Meeting Coverage:

Aspen Retinal Detachment Society

ARDS: 2021

ARDS Stays In-Person, Safely

Show Description +

Timothy G. Murray, MD, MBA, shares the importance of providing a safe environment for in-person learning, one year after the COVID-19 pandemic swept the globe.

Posted: 3/25/2021

Up Next

An Update on Surgical Approaches to Gene and Cell Therapies

Allen C. Ho, MD, Timothy G. Murray, MD, MBA


ROP in the Era of Anti-VEGF

R.V. Paul Chan, MD, MSc, MBA, FACS, Timothy G. Murray, MD, MBA

Advancements in Retinal Detachment Repair

Maria H. Berrocal, MD, Timothy G. Murray, MD, MBA

The Promise of Macular Reconstruction

Timothy W. Olsen, MD, Timothy G. Murray, MD, MBA

An Update on Brolucizumab One Year Later

Ryan Rich, MD; Timothy G. Murray, MD

Diabetic Retinopathy: Treat Them Early

Maria H. Berrocal, MD; Timothy G. Murray, MD

Track the History–and Future–of Anti-VEGF

Robert Avery, MD; Timothy G. Murray, MD

ARDS Stays In-Person, Safely

Timothy G. Murray, MD, MBA, shares the importance of providing a safe environment for in-person learning, one year after the COVID-19 pandemic swept the globe.

Posted: 3/25/2021


Please log in to leave a comment.

More From ARDS: 2021 Coverage

An Update on Brolucizumab One Year Later

Ryan Rich, MD; Timothy G. Murray, MD

Diabetic Retinopathy: Treat Them Early

Maria H. Berrocal, MD; Timothy G. Murray, MD

Track the History–and Future–of Anti-VEGF

Robert Avery, MD; Timothy G. Murray, MD